中国医药科学
中國醫藥科學
중국의약과학
CHINA MEDICINE AND PHARMACY
2013年
18期
89-90
,共2页
上消化道出血%肝硬化%奥曲肽
上消化道齣血%肝硬化%奧麯肽
상소화도출혈%간경화%오곡태
Upper gastrointestinal hemorrhage%Liver cirrhosis%Octreotide
目的:观察和探讨奥曲肽治疗肝硬化并上消化道出血的临床疗效。方法回顾性分析2010年1月~2012年6月间就诊的肝硬化并上消化道出血64例。其中33例患者在常规治疗的基础上应用奥曲肽作为止血药,设立为观察组,31例患者在常规治疗的基础应用垂体后叶素进行止血治疗,设立为对照组,比较两组治疗后的疗效。结果观察组33例患者治疗后的总有效率达93.9%,仅2例无效,对照组31例患者治疗后的总有效率达71.0%,无效例数比观察组多7例,两组总有效率比较,差异有显著性(P<0.05)。结论奥曲肽治疗肝硬化并上消化道出血疗效确切,无明显不良反应,值得推广和应用。
目的:觀察和探討奧麯肽治療肝硬化併上消化道齣血的臨床療效。方法迴顧性分析2010年1月~2012年6月間就診的肝硬化併上消化道齣血64例。其中33例患者在常規治療的基礎上應用奧麯肽作為止血藥,設立為觀察組,31例患者在常規治療的基礎應用垂體後葉素進行止血治療,設立為對照組,比較兩組治療後的療效。結果觀察組33例患者治療後的總有效率達93.9%,僅2例無效,對照組31例患者治療後的總有效率達71.0%,無效例數比觀察組多7例,兩組總有效率比較,差異有顯著性(P<0.05)。結論奧麯肽治療肝硬化併上消化道齣血療效確切,無明顯不良反應,值得推廣和應用。
목적:관찰화탐토오곡태치료간경화병상소화도출혈적림상료효。방법회고성분석2010년1월~2012년6월간취진적간경화병상소화도출혈64례。기중33례환자재상규치료적기출상응용오곡태작위지혈약,설립위관찰조,31례환자재상규치료적기출응용수체후협소진행지혈치료,설립위대조조,비교량조치료후적료효。결과관찰조33례환자치료후적총유효솔체93.9%,부2례무효,대조조31례환자치료후적총유효솔체71.0%,무효례수비관찰조다7례,량조총유효솔비교,차이유현저성(P<0.05)。결론오곡태치료간경화병상소화도출혈료효학절,무명현불량반응,치득추엄화응용。
Objective To observe and explore the clinical efficacy of octreotide for patients with liver cirrhosis combined with upper gastrointestinal hemorrhage. Methods A retrospective analysis of 64 patients with liver cirrhosis combined with upper gastrointestinal hemorrhage treated from January 2010 to June 2012 was conducted. Thirty-three patients receiving octreotide hemostatics on the basis of conventional therapy were chosen as the observation group, and 31 patients receiving hypophysin hemostatisc on the basis of conventional therapy were chosen as the control group. The the treatment efficacy of the two groups was compared. Results The total effective rate of the 33 patients in the observation group was 93.9%, with only 2 cases ineffective, and the total effective rate of the 31 patients in the control group was 71.0%, with 7 more ineffective cases than the observation group. The difference of efficacy between the two groups was statistically significant(P < 0.05). Conclusion Octreotide is effective in treating patients with liver cirrhosis combined with upper gastrointestinal hemorrhage, with no significant adverse reactions, thereby worthy of promotion and application.